|1.||Forero-Schwanhaeuser, Sergio: 10 articles (01/2012 - 10/2008)|
|2.||Cardozo, Linda: 8 articles (05/2013 - 10/2004)|
|3.||He, Weizhong: 8 articles (01/2013 - 12/2009)|
|4.||Ohtake, Akiyoshi: 8 articles (01/2010 - 05/2004)|
|5.||Sasamata, Masao: 8 articles (01/2010 - 05/2004)|
|6.||Kakizaki, Hidehiro: 6 articles (10/2015 - 09/2007)|
|7.||Miyata, Keiji: 6 articles (01/2010 - 08/2002)|
|8.||Sato, Shuichi: 6 articles (01/2010 - 05/2004)|
|9.||Yoshida, Masaki: 5 articles (10/2015 - 09/2007)|
|10.||Gotoh, Momokazu: 5 articles (10/2015 - 09/2007)|
|1.||Overactive Urinary Bladder (Overactive Bladder)
01/01/2012 - "In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer)."
11/01/2004 - "In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence. "
01/01/2015 - "Application of solifenacin at a dose of 5 mg in patients with overactive bladder significantly reduces the severity of symptoms. "
05/01/2014 - "Solifenacin also significantly improved the four quality of life subscales, total quality of life and symptom bother scores of the Overactive Bladder questionnaire. "
05/01/2014 - "Solifenacin significantly improved the total Overactive Bladder Symptom Score and also all subscores for the four symptoms (daytime frequency, urgency, night-time frequency and urgency incontinence). "
08/01/2006 - "Data from these trials show that solifenacin 5 and 10 mg once daily is significantly more effective than placebo at reducing urgency, incontinence, micturition frequency and nocturia and at increasing volume voided per micturition. "
12/01/2009 - "Solifenacin vs. placebo significantly improved daily episodes of urgency, incontinence and frequency but not nocturia. "
07/01/2007 - "Solifenacin significantly improved nocturia symptoms only in OAB patients without NP."
09/01/2005 - "Solifenacin significantly improved urgency, frequency, and nocturia symptoms and increased volume voided in OAB dry patients."
01/01/2015 - "Patients unsatisfied by therapy with solifenacin 5 mg/ day initially had more severe symptoms of the disease - significantly more urgency frequency, incontinence episodes, and nocturia. "
|3.||Urge Urinary Incontinence (Urge Incontinence)
08/01/2014 - "Solifenacin 5mg once daily improved urgency and other symptoms of OAB including frequency, urge incontinence, OABSS and International Prostatic Symptom Score. "
03/01/2005 - "In patients randomised to solifenacin in the double-blind studies, there were small incremental improvements in all efficacy parameters (reductions in episodes per 24 hours of urgency, reductions in frequency and urge incontinence, and increases in volume voided per micturition) over the course of the extension study. "
06/01/2013 - "Compared to the control group, solifenacin group had significantly lower total symptom score, urgency and urge incontinence scores. "
01/01/2010 - "Therapy with Solifenacin 5 and 10 mg has alleviated urgency in 82% and urge-incontinence in 88.9%. "
03/01/2007 - "Patients reporting urge incontinence as their most bothersome OAB symptom can be expected to demonstrate significant improvements in multiple patient-related outcomes following treatment with flexibly dosed solifenacin."
05/01/2015 - "In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms."
06/01/2006 - "Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence."
03/01/2014 - "Patients who have urgency urinary incontinence and high total OABSS have a tendency for dose escalation of solifenacin."
01/01/2014 - "To evaluate treatment success and tolerability of solifenacin among women with urinary urgency (UU) and urgency urinary incontinence (UUI). "
02/01/2008 - "A review of solifenacin in the treatment of urinary incontinence."
|5.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
12/01/2014 - "A post hoc analysis of the phase II Solifenacin and Tamsulosin in Males with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia trial (NCT00510406), a 12-week clinical trial in men with LUTS associated with BPH, assessed the measurement properties of six PPIUS-derived scores: mean score; maximum urgency score; total urgency and frequency score (TUFS; average sum of urgency scores over 3 days); and numbers of urgency episodes, urgency episodes of grade 3 or 4, and urgency incontinence episodes. "
01/01/2016 - "To evaluate the effect of a fixed-dose combination (FDC) of solifenacin and an oral-controlled absorption system (OCAS(™) ) formulation of tamsulosin (TOCAS) on health-related quality of life (HRQoL) in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). "
11/01/2015 - "Cost-Effectiveness Of A Fixed-Dose Combination Of Solifenacin Plus Tamsulosin Ocas For The Treatment Of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia In Spain."
01/01/2015 - "Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia."
01/01/2015 - "Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia."
|8.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|9.||trospium chloride (Ceris)
|2.||Prostatectomy (Retropubic Prostatectomy)
|4.||Deep Brain Stimulation
|5.||Continuous Positive Airway Pressure